Geron Corporation (GERN)
1.65
0.00 (0.00%)
At close: Mar 28, 2025, 3:59 PM
1.62
-1.52%
After-hours: Mar 28, 2025, 07:12 PM EDT
0.00% (1D)
| Bid | 1.6 |
| Market Cap | 1.05B |
| Revenue (ttm) | 75.91M |
| Net Income (ttm) | -172.11M |
| EPS (ttm) | -0.27 |
| PE Ratio (ttm) | -6.09 |
| Forward PE | -40.09 |
| Analyst | Buy |
| Ask | 1.72 |
| Volume | 15,300,172 |
| Avg. Volume (20D) | 14,873,906 |
| Open | 1.65 |
| Previous Close | 1.65 |
| Day's Range | 1.60 - 1.66 |
| 52-Week Range | 1.46 - 5.34 |
| Beta | 0.53 |
About GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes a...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 1996
Employees 229
Stock Exchange NASDAQ
Ticker Symbol GERN
Website https://www.geron.com
Analyst Forecast
According to 10 analyst ratings, the average rating for GERN stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 173.56% from the latest price.
Stock ForecastsNext Earnings Release
Geron Corporation is scheduled to release its earnings on May 1, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-32.07%
Geron Corporation shares are trading lower. The co...
Unlock content with
Pro Subscription
8 months ago
-7.14%
Geron shares are trading lower after the company announced the departure of CCO Anil Kapur.
